主要文件

查看所有文档

1420006

USP

Levodopa Related Compound B

Name: Levodopa Related Compound B
Brand: USP

United States Pharmacopeia (USP) Reference Standard

别名:

DL-3-O-Methyldopa, 3-Methoxytyrosine

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₀H₁₃NO₄

化学文摘社编号:

7636-26-2

分子量:

211.21

MDL number:

MFCD00063077

UNSPSC Code:

41116107

NACRES:

NA.24

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

levodopa

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(Cc1cc(c(cc1)O)OC)C(=O)O

InChI

1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)

InChI key

PFDUUKDQEHURQC-UHFFFAOYSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:

Carbidopa and Levodopa Orally Disintegrating Tablets
Levodopa
Carbidopa and Levodopa Tablets
Carbidopa and Levodopa Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.

T Müller et al.

Journal of neural transmission (Vienna, Austria : 1996), 114(11), 1457-1462 (2007-06-15)

The interval of line tracing performance is more associated to basal ganglia function due to the dependence on bradykinesia and rigidity. The other component of this task, the precision of execution of complex movement sequences, is more related to attention.

Caffeic acid improves the bioavailability of L-dopa in rabbit plasma.

Li-Hsuan Wang et al.

Phytotherapy research : PTR, 24(6), 852-858 (2009-11-27)

The impacts of caffeic acid (3,4-dihydroxycinnamic acid, CA) on the pharmacokinetics of levodopa (L-dopa) were studied in rabbits. A single dose of 5/1.25 mg kg(-1) L-dopa/carbidopa was administered alone or was co-administered with three different doses of caffeic acid (2.5

Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.

Thomas Müller et al.

Naunyn-Schmiedeberg's archives of pharmacology, 383(6), 627-633 (2011-05-03)

Elevation of plasma total homocysteine concentrations were observed in levodopa/dopa decarboxylase inhibitor (DDI)-treated patients with Parkinson's disease (PD). Degradation of levodopa to 3-O-methyldopa via the enzyme catechol-O-methyltransferase (COMT) is a methyl group demanding reaction. It generates homocysteine from the methyl

查看所有相关文献

全球贸易项目编号

货号	GTIN
1420006-50MG	04061833860533